BRCA2 and cancer: To identify potential novel drugs for cancers with BRCA2 mutations, we tested a total of 17 commercially available inhibitors (Supplementary Table 1) by clonogenic assays in isogenic BRCA2 knockout and wild type (WT) HCT116 cell line pairs published by us21.